Therapeutic Focus – Cystic fibrosis market looking for breath of fresh air

Date December 14, 2009

With the thumbs up from an FDA advisory committee last week for Gilead’s aztreonam, the rather staid world of cystic fibrosis treatments could finally get a new therapy, to help in the battle in this hard to treat disease. The last approved drug in field was Novartis’ TOBI in 1998.

But as an analysis from EP Vantage shows, while aztreonam, also known as Cayston, will be a new treatment, it like the majority of drugs approved for use in the disorder helps to alleviate the symptoms of CF rather than modify the disease. As the table below shows many marketed drugs are either pancreatic enzymes that help keep patients’ weight up by aiding them to fight against illness, or like Cayston an antibiotic used to treat the lung infections associated with CF.

This content is written, edited and published by EP Vantage and is distributed by Evaluate Ltd. All queries regarding the content should be directed to: news@epvantage.com

EP Vantage is a unique, forward-looking, news analysis service tailored to the needs of pharma and finance professionals. EP Vantage focuses on the events that will define the future of companies, products and therapy areas, with detailed financial analysis of events in real-time, including regulatory decisions, product approvals, licensing deals, patent decisions, M&A.

Drawing on Evaluate, an industry-leading database of actual and forecast product sales and financials, EP Vantage gives readers the insight to make value-enhancing decisions.

EP Vantage SM ©2018 EP Vantage Ltd